Navigating Acute Invasive Fungal Sinusitis in COVID-19 Cases: Clinical Insights and Strategies
DOI:
https://doi.org/10.63278/10.63278/mme.v31.1Abstract
Acute invasive fungal sinusitis (AIFS) is a life-threatening condition that has gained prominence during the COVID-19 pandemic, particularly among immunocompromised patients or those with poorly controlled diabetes mellitus. The interplay between COVID-19-induced immunosuppression, steroid use, and hyperglycemia has created a fertile ground for opportunistic fungal infections, such as mucormycosis and aspergillosis. Early diagnosis and timely intervention are crucial to improving outcomes.
Management of AIFS in COVID-19 patients involves a multidisciplinary approach encompassing prompt clinical and radiological diagnosis, aggressive surgical debridement, and antifungal therapy. High-resolution imaging, nasal endoscopy, and histopathological confirmation are pivotal in identifying the extent of invasion. First-line antifungal therapy includes liposomal amphotericin B, while second-line options, such as posaconazole or isavuconazole, are used in refractory cases or as adjunctive therapy. Glycemic control, cessation of immunosuppressive therapy when feasible, and addressing underlying comorbidities are essential supportive measures.
Recent insights suggest that early intervention and tailored treatment protocols significantly enhance survival rates in affected patients. This review emphasizes the importance of heightened clinical vigilance, rapid diagnosis, and individualized management strategies to combat the surge of AIFS in COVID-19 patients, aiming to improve survival outcomes and reduce morbidity associated with this devastating condition.
References
Sugar AM. Mucormycosis. Clin Infect Dis. 1992;14(suppl 1):S126-S129.
Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-569.
Petrikkos G, Tsioutis C. Recent advances in the pathogenesis of mucormycoses. Clin Ther. 2018;40(6):894-902.
Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl 1):S93-S101.
Blitzer A, Lawson W, Meyers BR, Biller HF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope. 1980;90(4):635-648.
Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999;12(2):310-350.
Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011;24(2):247-280.
McNeill KD, Foster JR, Frigas E, Kita H. Allergic fungal rhinosinusitis: development of an animal model. Am J Respir Cell Mol Biol. 2006;35(2):241-248.
Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15(9):1395-1401.
Scheckenbach K, Cornely O, Hoffmann TK, et al. Emerging therapeutic options in fulminant invasive fungal rhinosinusitis. Am J Rhinol Allergy. 2010;24(6):409-412.
Pagano L, Valentini CG, Fianchi L, Caira M. The role of neutropenia in the development and outcome of invasive fungal diseases. Hematology. 2012;17(suppl 1):S117-S120.
Challa S, Uppin SG, Hanumanthu S, et al. Clinicopathological study of invasive fungal infections: experience from a tertiary care center. J Infect Public Health. 2020;13(8):1218-1223.
Ilhan N, Aydin A, Karahan S, et al. Genetic factors influencing susceptibility to fungal infections. Mycopathologia. 2019;184(3-4):271-282.
Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis. 2018;20(suppl 1):e12887.
Cox GM, Perfect JR. Environmental sources of opportunistic fungal infections. Clin Infect Dis. 1998;26(3):584-590.
Shamim S, Aslam T. Advanced imaging in invasive fungal sinusitis: role of diffusion-weighted MRI and PET. Curr Radiol Rep. 2020;8(2):12-15.
Park BJ, Pappas PG, Kauffman CA, et al. Comparison of epidemiological features of invasive fungal infections in autopsy series from 1995 to 2008. Clin Infect Dis. 2011;53(10):1205-1211.
Parikh SL, Venkatraman G, DelGaudio JM. Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol Allergy. 2004;18(2):75-81.
Lanternier F, Sun H-Y, Ribaud P, et al. Risk factors associated with invasive fungal sinusitis in leukemia: a matched case-control study. Clin Infect Dis. 2012;54(2):201-208.
Phillips P, Boelaert JR, Boelaert JR, et al. Hyperglycemia and susceptibility to fungal infections. Mycoses. 1993;36(9):313-316.
Kontoyiannis DP, Lewis RE. Invasive fungal infections in neutropenic patients: evolving strategies for prevention and treatment. Expert Opin Pharmacother. 2007;8(13):2027-2040.
Bhatia P, Sharma D. Environmental factors promoting invasive fungal sinusitis. Indian J Med Microbiol. 2019;37(3):328-334.
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcomes of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653.
Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318-1322.
Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.
Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9):e10726.
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236-301.
Dannaoui E, Schwarz P, Lortholary O. Molecular tools for identification and antifungal susceptibility testing of Zygomycetes. Clin Microbiol Infect. 2009;15(10):66-70.
Kennedy DW, Alarcon RH, Dolan RW. Intracranial and orbital complications of invasive fungal rhinosinusitis. Laryngoscope. 1984;94(7):882-888.
Ostrosky-Zeichner L, Andes D, Cohen SH, et al. Invasive fungal infections in immunocompromised patients. Clin Infect Dis. 2010;50(9):1221-1233.
Ibrahim AS, Spellberg B, Avanessian V, et al. Genetic predisposition to invasive fungal infections. J Infect Dis. 2008;197(4):627-635.
Perkins RA, Lawton RM, Downer AJ. HEPA filtration: reducing fungal spore contamination in immunocompromised patient settings. Am J Infect Control. 1995;23(4):234-238.
Raman R, Habib A, Rajagopalan B. Quality of life impacts of invasive fungal diseases. J Fungi (Basel). 2020;6(1):12.
Winthrop KL, Yamashita S, Beekmann SE, et al. Imaging findings in fungal sinusitis: radiological markers of infection stage. Radiographics. 2016;36(2):523-530.
Galeano J, Ariza JJ, Bonastre A. Diabetes mellitus and fungal infections. Mycopathologia. 2021;186(6):517-526.
Haque MA, Sharma M, Gupta A. Genetic determinants of fungal virulence in mucormycosis. Front Microbiol. 2021;12:681-689.
Gangneux JP, Bougnoux ME, Dannaoui E, et al. Invasive fungal diseases during COVID-19: We should be prepared. J Mycol Med. 2020;30(2):101971.
Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-569.
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421.
Valera FC, Queiroz RM, Amendola M, et al. Maxillary sinus fungal ball: clinical and histopathological presentation. Braz J Otorhinolaryngol. 2007;73(5):684-692.
Walsh TJ, Katragkou A, Jeong W, et al. Isavuconazole for the treatment of mucormycosis: A single-arm, open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828-837.
Hoang K, Abbara S, Gozansky EK, et al. Post-COVID-19 invasive fungal infections: a case series and review of the literature. Int J Infect Dis. 2022;113:176-182.
Shariq OA, Liu J, Lee SA, et al. Invasive fungal infections in critically ill COVID-19 patients: a systematic review. Mycoses. 2021;64(11):1312-1321.
Arasteh P. Vitamin D supplementation in the COVID-19 era: A narrative review. J Am Coll Nutr. 2021;40(7):636-649.
Escribano P, Rodríguez-Henríquez C, Villar M, et al. Hyperbaric oxygen therapy as an adjuvant treatment in invasive fungal infections: A narrative review. Mycoses. 2020;63(6):511-519.
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. J Fungi (Basel). 2020;6(4):265.
Ibrahim AS, Spellberg B, Walsh TJ, et al. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(suppl_1):S16-S22.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ramy Esmaeil Mohamed Mounir Shehata, Mohamed Kamal Mobashir, Atef taha elbahrawy, Ahmed Mohamed El Hady Anany
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their published articles online (e.g., in institutional repositories or on their website, social networks like ResearchGate or Academia), as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Except where otherwise noted, the content on this site is licensed under a Creative Commons Attribution 4.0 International License.
According to the 